Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
Loading...
Embargo End Date
ICR Authors
Authors
Bohnacker, T
Prota, AE
Beaufils, F
Burke, JE
Melone, A
Inglis, AJ
Rageot, D
Sele, AM
Cmiljanovic, V
Cmiljanovic, N
Bargsten, K
Aher, A
Akhmanova, A
Díaz, JF
Fabbro, D
Zvelebil, M
Williams, RL
Steinmetz, MO
Wymann, MP
Prota, AE
Beaufils, F
Burke, JE
Melone, A
Inglis, AJ
Rageot, D
Sele, AM
Cmiljanovic, V
Cmiljanovic, N
Bargsten, K
Aher, A
Akhmanova, A
Díaz, JF
Fabbro, D
Zvelebil, M
Williams, RL
Steinmetz, MO
Wymann, MP
Document Type
Journal Article
Date
2017-03-09
Date Accepted
Abstract
<jats:title>Abstract</jats:title><jats:p>BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization. Here, we developed two chemical derivatives that differ from BKM120 by only one atom. We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors. Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K. Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs. Our results raise concerns over BKM120’s generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies.</jats:p>
Citation
NATURE COMMUNICATIONS, 2017, 8
Source Title
Publisher
Springer Science and Business Media LLC
ISSN
2041-1723
eISSN
Collections
Research Team
Cancer Informatics